The tweet was deleted by the author.
But we saved everything 🙂.
Jon Najarian, co-founder of Market Rebellion at https://x.com/jonnajarian, reports that Inhibrx Biosciences rose 7 percent in after-hours trading. The company announced it will release interim results on May 11 from its phase 2 trial of INBRX-106 for first-line head and neck squamous cell carcinoma.
Najarian notes that optimism is growing regarding the anticipated results.
Najarian has previously covered major deals in sports and finance, including Big12’s five-year private capital agreement with RedBird Capital. He has also commented on high-profile disputes involving net worth disclosures and property valuations. The latest move in Inhibrx Biosciences follows a series of timely updates on significant market developments.